Company profile
Monte Rosa Therapeutics, Inc.
NASDAQ: GLUE · Healthcare · Biotechnology
#327 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
54DFH 63DQ 40GM —SS 57
v0.1 · 55/100 weight · provisional
↑ market scale, Altman-Z · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$28.7M
Rev growth YoY (TTM)
-83.9%
Net income (FY)
-$38.6M
Employees
150
as of 2026-08-09
Market cap
$1.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$123.7M$123.7M2025
Net income-$38.6M-$38.6M2025
Operating income-$54.2M-$54.2M2025
Total assets$448.7M$448.7M2025
Liabilities$215.6M$215.6M2025
Equity$233.1M$233.1M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Monte Rosa Therapeutics, Inc.’s revenue?
Monte Rosa Therapeutics, Inc. booked $123.7M in FY2025 revenue, growing 64% year over year — faster than most Healthcare companies we track, at a -31.2% net margin.
Peers · Healthcare
UpHealth, Inc.——Niagen Bioscience Inc78B+Xencor, Inc.59CAtara Biotherapeutics, Inc.44DCareCloud, Inc.73BSmileDirectClub Inc Class A——Neighbors
Suffolk →Key facts
CEOMarkus Warmuth
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: GLUE
Employees150
IPO date2021-06-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.